Healthcare Sep 18, 2020 10:58 AM (GMT+8) · EqualOcean
IMAB (IMAB:Nasdaq) announced together with MorphoSys that their TJ210/MOR210, an in-process new medicine, was approved by the Food and Drug Administration (FDA) to enter the clinical trial. The trial aims to test the safety, tolerance and pharmacodynamics. IMAB is biotechnology that focuses on developing precision medicines for tumor immunology and autoimmune disease.

Source: VCbeat